WEP has developed two proprietary biopolymer technologies, PolyPEG and GlycoPol, and the company plans to license deals for these technologies this year.
WEP’s PolyPEG is a low viscosity comb polymer for extending the duration of action of biopharmaceuticals and GlycoPol is a novel glycopolymer for targeting the delivery of therapeutic agents to specific glycan receptors on cells.
PolyTherics’ proprietary conjugation technologies, TheraPEG, CyPEG and HiPEG, have been used to attach polymers to specific sites on proteins and peptides to extend their duration of action and to produce antibody drug conjugates.
PolyTherics CEO John Burt said the acquisition allows the combined businesses to provide a portfolio of best-in-class technologies to enable better biopharmaceuticals, benefiting patients.